ID: MRFR/HC/7123-HCR | February 2023 | Region: Global | 90 Pages
Thalassemia Treatment Market is expected to reach USD 14.8 Billion by 2030, registering a CAGR of 10.50% during the forecast period.
$14.8 Billion
10.50%
North America
2022-2030
Thalassemia Treatment Market is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%. Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Thalassemia Treatment Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the Thalassemia Treatment Market.
Market Drivers
Market Restraints
Thalassemia Treatment Market Segmentation
By Type
By Treatment
By End-User
By Region
Thalassemia Treatment Market Key Players
Report Attribute/Metric | Details |
---|---|
Market Size | USD 3763 Million |
CAGR | 10.4% |
Base Year | 2019 |
Forecast Period | 2025 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Treatment, End-User and Region |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Novartis AG (Switzerland), Bluebird Bio, Inc. (US), Kiadis Pharma (Netherlands), CELGENE CORPORATION (US), Sangamo Therapeutics (US), Acceleron Pharma, Inc. (US), Gamida Cell (Israel) |
Key Market Opportunities |
|
Key Market Drivers |
|
Global Thalassemia Treatment Market is projected to grow at approximately 10.4% CAGR during the assessment period (2019-2025).
Global Thalassemia Treatment Market is estimated to reach a valuation of approx. USD 3763 MN by the end of 2025
Rising thalassemia diagnosed cases, increasing pipeline drugs and awareness about the condition & available treatment options, are major tailwinds pushing the growth of the Global Thalassemia Treatment Market.
North America holds the largest share in the Global Thalassemia Treatment Market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), Bluebird Bio, Inc. (US), Kiadis Pharma (Netherlands), Celgene Corporation (US), Sangamo Therapeutics (US), Acceleron Pharma, Inc. (US), and Gamida Cell (Israel), are some of the top players operating in the Global Thalassemia Treatment Market.